Want to see HK:1548 full AI Analyst Report?
Genscript Biotech (1548) AI Stock Analysis
Top Page
Genscript Biotech
(HKEX:1548)
The score is driven primarily by improved operating fundamentals and cash flow in 2025 with manageable leverage (financial performance), reinforced by a strongly positive earnings call featuring raised guidance and robust H1 growth/margin expansion. Offsetting factors are valuation concerns tied to negative/unstable earnings (negative P/E) and only mixed technicals (below the 20-day average despite being above longer-term averages).
Genscript Biotech (1548) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 10.12B
- Dividend Yield
- ―
- Average Volume (3M)
- 45.19M
- Price to Earnings (P/E)
- -14.9
- Beta (1Y)
- 1.49
- Revenue Growth
- 53.48%
- EPS Growth
- -120.02%
- Country
- Hong Kong
- Employees
- 6,135
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Genscript Biotech Business Overview & Revenue Model
Company Description
Operating as an investment holding company, Genscript Biotech Corporation, established in 2002 and headquartered in Nanjing, People's Republic of China, specializes in the global provision of innovative life science research solutions, encompassing b...
How the Company Makes Money
GenScript makes money primarily by selling products and providing fee-for-service R&D and manufacturing services to third parties. Key revenue streams include: (1) Life-science research products and services: revenue from catalog and custom offerings...
Genscript Biotech Earnings Call Summary
Overall the call was strongly positive: the company reported robust top-line growth (USD 404.2M, +27.3%), record adjusted net profit (+203.3% to USD 62.5M), significant margin expansion and raised guidance, while highlighting clear strategic advantages in AI-enabled validation and a strong balance sheet. The main negatives are a still-unprofitable ProBio (though materially improved), Bestzyme's modest growth and widened operating loss, and execution/demand risks tied to the pace of AIDD adoption and scaling protein-side automation. On balance, highlights substantially outweigh lowlights.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management raised full‑year guidance: Life Science Services revenue growth 25–30% with adjusted gross margin >55% and adjusted operating margin >25%; ProBio revenue growth 25–30% with positive EBITDA expected in 2027; and Bestzyme revenue growth 8–10% with adjusted gross margin >43%. This follows a strong H1 baseline (group revenue US$404.2M, +27.3% YoY; adjusted net profit US$62.5M, +203.3%; group gross profit US$206.7M, +48%); LSG delivered US$319M revenue (+28.8%), adjusted gross profit US$185M (+46.1%) and adjusted operating profit US$94M (+102.8%) with adjusted gross margin 57.8% (55.4% ex U.S. tariff refunds) and operating margin 29.5% (27.1% same basis); ProBio H1 revenue US$61.1M (+34.2%), adjusted gross profit US$8.3M and adjusted EBITDA loss narrowed to US$6.5M (vs. -US$16.8M); Bestzyme H1 revenue US$30.4M (+7.4%) and adjusted gross profit US$13M (+14%). Management also disclosed H1 CapEx US$48.4M and full‑year CapEx ~US$130M, cash ≈US$830M, a 1.5x YoY surge in gene‑to‑protein ROI, and expects AIDD orders to double in H2 as a driver of continued upside.
Genscript Biotech Financial Statement Overview
Summary
Operations improved in 2025 with strong revenue growth (+74.12% YoY), healthy gross margin (~57.7%) and EBIT margin (~26.6%), plus a return to positive operating cash flow (~325.5M) and free cash flow (~241.7M). Offsetting this, net income is highly volatile (2025 large net loss after an unusually large 2024 profit), and free cash flow has been inconsistent historically (negative in 2024 and persistent burn in 2020–2023). Balance sheet leverage is relatively conservative (debt-to-equity ~0.13).
Income Statement
54NeutralBalance Sheet
72PositiveCash Flow
60Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 844.00M | 959.53M | 594.49M | 560.48M | 625.70M | 490.10M |
| Gross Profit | 438.79M | 553.20M | 272.13M | 270.63M | 304.08M | 282.52M |
| EBITDA | 205.25M | 329.29M | 83.16M | 100.24M | -373.73M | -467.19M |
| Net Income | -636.40M | -532.83M | 2.96B | -95.48M | -226.85M | -358.71M |
Balance Sheet | ||||||
| Total Assets | 4.79B | 4.85B | 5.28B | 3.39B | 2.55B | 2.23B |
| Cash, Cash Equivalents and Short-Term Investments | 831.18M | 843.01M | 621.18M | 1.93B | 1.46B | 1.41B |
| Total Debt | 254.68M | 258.84M | 723.74M | 416.99M | 349.80M | 156.45M |
| Total Liabilities | 881.62M | 876.30M | 954.91M | 1.34B | 1.18B | 846.17M |
| Stockholders Equity | 3.88B | 3.96B | 4.32B | 1.39B | 1.01B | 1.05B |
Cash Flow | ||||||
| Free Cash Flow | 50.30M | 241.69M | -72.27M | -444.62M | -336.40M | -269.83M |
| Operating Cash Flow | 149.59M | 325.52M | 75.65M | -286.91M | -120.29M | -136.79M |
| Investing Cash Flow | -73.16M | -171.95M | -1.46B | -357.73M | -443.30M | -212.55M |
| Financing Cash Flow | -183.50M | -144.89M | 66.52M | 1.07B | 419.32M | 902.14M |
Genscript Biotech Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1548, the sentiment is Positive. The current price of 35.02 is below the 20-day moving average (MA) of 37.41, below the 50-day MA of 36.74, and above the 200-day MA of 19.64, indicating a neutral trend. The MACD of -0.77 indicates Positive momentum. The RSI at 47.80 is Neutral, neither overbought nor oversold. The STOCH value of 75.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1548.
Genscript Biotech Peers Comparison
Overall Rating
HK:226981Outperform
HK:187373Outperform- HK:154864Neutral
HK:152163Neutral
HK:682154Neutral
HK:375953Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:2269 | 81Outperform | HKD 183.11B | 31.19 | 10.51% | ― | 21.93% | 21.94% |
| HK:1873 | 73Outperform | HKD 2.60B | 12.92 | 4.45% | ― | 7.38% | 7.90% |
| HK:1548 | 64Neutral | HKD 79.58B | -14.95 | -16.23% | ― | 53.48% | -120.02% |
| HK:1521 | 63Neutral | HKD 3.04B | 36.53 | 3.02% | ― | 10.32% | 178.23% |
| HK:6821 | 54Neutral | HKD 54.78B | 40.79 | 6.66% | 1.44% | 23.95% | 18.73% |
| HK:3759 | 53Neutral | HKD 80.45B | 41.79 | 10.93% | 0.85% | 24.21% | 19.72% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:1548 | Genscript Biotech Corporation | 35.02 | 17.98 | 105.52% | |
| HK:2269 | Wuxi Biologics (Cayman) | 44.48 | 8.86 | 24.87% | |
| HK:3759 | Pharmaron Beijing Co., Ltd. Class H | 26.98 | 1.65 | 6.50% | |
| HK:1521 | Frontage Holdings Corp. | 1.49 | 0.32 | 27.35% | |
| HK:1873 | Viva Biotech Holdings | 1.25 | -1.14 | -47.70% | |
| HK:6821 | Asymchem Laboratories (Tianjin) Co., Ltd. Class H | 103.90 | 19.42 | 22.99% |
Genscript Biotech Corporate Events
Legend Biotech Posts US$710 Million Quarterly Sales for CARVYKTI
Legend Biotech, an associate of Genscript Biotech, reported preliminary net trade sales of approximately US$710 million for CARVYKTI for the quarter ended 30 September 2026, under its collaboration and license agreement with Janssen Biotech. The stro...
Genscript Biotech Halves Trading Lot Size to Boost Liquidity on Hong Kong Market
Genscript Biotech Corporation plans to halve the trading board lot size of its ordinary shares on the Hong Kong Stock Exchange from 2,000 to 1,000 shares, effective 9:00 a.m. on October 14, 2026. The move is designed to reduce the minimum transaction...
Genscript Biotech Joins Lilly’s AI Drug Discovery Platform Amid Share Price Surge
Genscript Biotech has entered into an agreement to join Lilly TuneLab, an AI-enabled drug discovery platform created by Eli Lilly, under which it will provide preferred-rate wet lab services to member companies to generate experimental data and valid...
Genscript Biotech Reshapes Board Committees After Director’s Passing
Genscript Biotech Corporation has announced the passing of independent non-executive director Dr. Alphonse Galdes, who had served on the board and as a member of the audit committee since September 2024. The board expressed its appreciation for his g...
Genscript Biotech Details Board and Committee Structure in Governance Update
Genscript Biotech has disclosed the latest composition of its board and the roles directors hold across five key committees, including audit, remuneration, nomination, risk management and ESG, and strategy. The allocation of chairmanships and members...
Genscript Biotech Raises HK$2.33 Billion Through Hong Kong Share Placing
Genscript Biotech Corporation has completed a placing of 77,126,000 new shares under its general mandate, representing about 3.38% of its enlarged share capital. The shares were placed to at least six independent investors at HK$30.50 per share, rais...
Genscript Biotech to Raise HK$2.33 Billion via Discounted Share Placing for AIDD Expansion
Genscript Biotech has entered into a placing agreement to issue 77,126,000 new shares at HK$30.50 each to at least six professional or institutional investors, raising estimated net proceeds of about HK$2.33 billion. The placing shares represent roug...
GenScript Biotech Updates Cayman Islands Corporate Service Provider Names
GenScript Biotech has changed the name of its principal share registrar and transfer office in the Cayman Islands from Harneys Services (Cayman) Limited to Ascentium (Cayman) Limited, while keeping the existing address. The company has also updated t...
Genscript Plans Hong Kong Spin-Off Listing for Probio Technology
Genscript Biotech Corporation has announced plans to spin off and separately list its indirect subsidiary Probio Technology Limited on the Main Board of the Stock Exchange of Hong Kong. Probio runs the group’s Biologics and Advanced Therapy con...
Genscript Biotech Clarifies Board Structure and Committee Roles
Genscript Biotech has detailed the composition of its board of directors, naming Chairman Jiange (Robin) Meng, President Ye (Sally) Wang and other executive directors, alongside six independent non-executive directors drawn from diverse scientific an...
Genscript Biotech Posts Strong Core Growth but Reports Interim Loss on Legend Impact
Genscript Biotech reported strong underlying growth for the six months ended 30 June 2026, with revenue rising 27.3% year-on-year to US$404.2 million and gross profit jumping 48.0% on the same basis. The adjusted net profit reached US$62.5 million, a...
Genscript Highlights Legend Biotech’s Q2 Results and Cautions Investors
Genscript Biotech has released a voluntary announcement informing investors that its associate, Legend Biotech Corporation, has filed its second-quarter 2026 financial results and recent business highlights with the U.S. Securities and Exchange Commi...
Genscript Biotech Sets August Board Meeting to Approve Interim Results
Genscript Biotech Corporation has scheduled a board meeting in the United States for 15 August 2026 to review and approve its interim results for the six months ended 30 June 2026. The board will also decide on the publication of these results and co...
Genscript Highlights Strong CARVYKTI Sales via Legend Biotech, Urges Investor Caution
Genscript Biotech announced that its associate Legend Biotech reported preliminary net trade sales of approximately US$657 million for CARVYKTI for the quarter ended 30 June 2026, under a collaboration and license agreement with Janssen Biotech, Inc....
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 14, 2026